KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Q3 2025 value amounting to -$271.4 million.

  • Jazz Pharmaceuticals' Deferred Taxes fell 32141.79% to -$271.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$384.0 million, marking a year-over-year decrease of 5876.87%. This contributed to the annual value of -$208.3 million for FY2024, which is 1994.1% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Deferred Taxes stood at -$271.4 million, which was down 32141.79% from -$66.4 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Deferred Taxes high stood at $190.7 million for Q2 2021, and its period low was -$271.4 million during Q3 2025.
  • For the 5-year period, Jazz Pharmaceuticals' Deferred Taxes averaged around -$56.5 million, with its median value being -$64.6 million (2022).
  • Its Deferred Taxes has fluctuated over the past 5 years, first skyrocketed by 111477.76% in 2021, then tumbled by 43066.98% in 2022.
  • Jazz Pharmaceuticals' Deferred Taxes (Quarter) stood at -$27.4 million in 2021, then tumbled by 430.67% to -$145.4 million in 2022, then skyrocketed by 75.31% to -$35.9 million in 2023, then soared by 93.44% to -$2.4 million in 2024, then plummeted by 11424.84% to -$271.4 million in 2025.
  • Its last three reported values are -$271.4 million in Q3 2025, -$66.4 million for Q2 2025, and -$43.8 million during Q1 2025.